The Cancer Drug Resistance Company
Scandion Oncology is a clinical-stage biotechnology company discovering and developing first-in-class medicines aimed at treating cancer which is resistant to current treatment options.
We are at the forefront of this field, developing novel medicines that address cancer’s resistance against treatment. Our aim is to make existing cancer treatments work better and longer, thereby potentially prolonging and improving the life of patients who would otherwise have a high risk of dying from their cancer.
Cancer drug resistance is an often neglected problem in the current landscape of existing treatments and novel therapeutics under development for cancer. We believe cancer drug resistance should be seen as an independent medical challenge that warrants a tailored approach.
Globally, close to 10 million patients die every year from treatment resistant cancers, and our medicines are relevant in several different cancers as oral add-on drugs to existing market leading therapies. That makes both our medical and commercial potential significant.
Our vision is to overcome cancer drug resistance, in order to improve lives for cancer patients and their families.